Loading...

TRUE LUNG CLEARANCE INDEX (LCI)
IN CLINICAL PRACTICE

PulmoTrace is a Danish company that owns a unique technology to measure kinetics of washin and washout of tracer gases in the lungs. This enables us to provide a very sensitive estimate of small airway function in a simple manner.

We offer an FDA approved and CE marked device, Innocor, enabling a reimbursable LCI test, ready for routine clinical use.

PulmoTrace is engaged in several R&D projects that we anticipate will enhance our technology even further in the years to come. If you have an interest in getting involved in this type of research please do not hesitate to contact us.

TECHNOLOGY

OUR TECHNOLOGY
The PulmoTrace technology is based on the combination of an extremely sensitive Photoacoustic Spectroscopy (PAS) gas analyzer and advanced computer models of gas transport in the human lungs.

THE LCI TEST
In the true LCI test, the patient is breathing a low concentration of a blood insoluble tracer gas, SF6. During washout the patient is breathing air and the SF6 concentration is followed until it reaches 1/40 of the concentration at the end of washin. At this point, the LCI point, the total expired volume recorded during washout is calculated and it is divided by the lung volume. This is by definition Lung Clearance Index, LCI. In other words, the LCI is the number of times the patient needs to replace his lung volume to decrease the tracer gas concentration by a factor of 40. A patient with unequal distribution of ventilation has significantly higher LCI than a normal subject.

The advantages of the true LCI test compared to the conventional FEV1 test are primarily:

  1. The test is performed without special breathing maneuvers and can therefore be applied to the preschool age group.
  2. Unlike FEV1, LCI is dependent not only on convective gas flow but also on gas transport by diffusion. The test is therefore also sensitive to abnormalities in the small airways and thus typically abnormal earlier in a disease than FEV1.

270515 Pulmotrace_Innovision_31732
Pulmotrace_Innovision_3Pulmotrace_Innovision_4

PRODUCT

INNOCOR
Our LCI technology is implemented in the product Innocor, which meets the Guidelines of the ERS/ATS Concensus Statement. Innocor is very easy to use and the operator needs to be trained only 1 – 2 hours by one of our specialists. It requires very few calibration procedures and patient compliance is easily obtained. The system is particularly suited for use in the preschool age group because of very low dead space and fast response time.

Product data sheet

The specifications compared to the Guidelines:

technical-specifications

SCIENTIFIC LITERATURE

SELECTED PUBLICATIONS FROM THE LAST 3 YEARS
RELATING TO PULMOTRACE TECHNOLOGIES

Infant lung function: first report of a novel infant multiple breath washout
apparatus.

Shawcross A, Murray C, Aurora P, Horsley A.
Journal of Cystic Fibrosis. Jun 2015, Vol 14, suppl 1, Page S48.

Enhanced photoacoustic gas analyser response time and impact on accuracy at fast ventilation rates during multiple breath washout.
Horsley A, Macleod K, Gupta R, Goddard N, Bell N.
PLoS One. 2014 Jun 3;9(6).

Improving the multiple breath washout test: closed circuit washin with a novel
bolus gas delivery system substantially reduces washin time and does not alter washout.

Horsley A.
Journal of Cystic Fibrosis. Vol. 13, S79 June, 2014.

Lung clearance index in adults with non-cystic fibrosis bronchiectasis.
Gonem S, Scadding A, Soares M, Singapuri A, Gustafsson P, Ohri C, Range S, Brightling CE, Pavord I, Horsley A, Siddiqui S.
Respir Res. 2014 May 18;15:59.

Lung clearance index is a repeatable and sensitive indicator of radiological changes in bronchiectasis.
Rowan SA, Bradley JM, Bradbury I, Lawson J, Lynch T, Gustafsson P, Horsley A, O’Neill K, Ennis M, Elborn JS.
Am J Respir Crit Care Med. 2014 Mar 1;189(5):586-92.

Validation of a photoacoustic gas analyser for the measurement of functional
residual capacity
 
using multiple-breath inert gas washout.
Gonem S, Singer F, Corkill S, Singapur A, Siddiqui S, Gustafsson P.
Respiration. 2014;87(6):462-8.

Lung clearance index: should we really go back to nitrogen washout?
Nielsen JG.
Eur Respir J. 2014 Feb;43(2):655-6.

Age and height dependence of lung clearance index and functional residual
capacity.
Lum S, Stocks J, Stanojevic S, Wade A, Robinson P, Gustafsson P, Brown M, Aurora P, Subbarao P, Hoo AF, Sonnappa S.
Eur Respir J. 2013 Jun;41(6):1371-7.

Assessment of clinical response to ivacaftor with lung clearance index in cystic
fibrosis patients with a G551D-CFTR mutation and preserved spirometry:
a randomised controlled trial
.
Davies J, Sheridan H, Bell N, Cunningham S, Davis SD, Elborn JS, Milla CE, Starner TD, Weiner DJ, Lee PS, Ratjen F
Lancet Respir Med. 2013 Oct;1(8):630-8. Epub 2013 Sep 10.

Consensus statement for inert gas washout measurement using multiple- and
single- breath tests
.
Robinson PD, Latzin P, Verbanck S, Hall GL, Horsley A, Gappa M, Thamrin C, Arets HG, Aurora P, Fuchs SI, King GG, Lum S, Macleod K, Paiva M, Pillow JJ, Ranganathan S, Ratjen F, Singer F, Sonnappa S, Stocks J, Subbarao P, Thompson BR, Gustafsson PM.
Eur Respir J. 2013 Mar;41(3):507-22.

Evaluation of the impact of alveolar nitrogen excretion on indices derived from
multiple breath nitrogen washout
.
Nielsen N, Nielsen JG, Horsley AR.
PLoS One. 2013 Sep 9;8(9).

Lung clearance index is a sensitive, repeatable and practical measure of airways
disease in adults with cystic fibrosis.

Horsley AR, Gustafsson PM, Macleod KA, Saunders C, Greening AP, Porteous DJ, Davies JC, Cunningham S, Alton EW, Innes JA.
Thorax. 2008 Feb;63(2):135-40.

ABOUT

PULMOTRACE: A SPECIALIST IN LUNG FUNCTION TESTING

PulmoTrace is a spin-out from Innovision ApS, Denmark. The company is owned by Innovision and Venture Capital partners. We intend to utilize our key technologies to improve diagnostics and management of patients with various pulmonary diseases including Cystic Fibrosis, Asthma and COPD.

PulmoTrace is producing, selling and servicing the product Innocor in EU, Canada and United States.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

THE TEAM

OUR TEAM CONSISTS OF MEDICAL DOCTORS, ENGINEERS
AND RESPIRATORY THERAPISTS

KP_SH

KNUD PEDERSENCTO

(+45) 63 10 06 20 (GMT+1)
kp@pulmotrace.com

Knud holds an MSc degree in Electrical and Biomedical Engineering. He has more than 25 years experience with respiratory gas analysis, advanced gas exchange methods and design and development of medical products for use in clinical environments and manned space flights.

JGN_sh

JØRGEN GRØNLUND NIELSENCEO

(+45) 20 78 91 40 (GMT+1) or
(+1) 404 769 0588 (GMT-5)
jgn@pulmotrace.com

Jørgen is an MD and PhD in Gas Exchange Physiology. He founded Innovision in 1986 and two other Danish companies (Damec and PAS Technology) that have both been sold to industrial investors. Jørgen has published 40 papers in peer reviewed journals relating to various gas exchange methods including mathematical modelling and in vivo validations. Pubmed entrance is J. Grønlund. Jørgen is also the author of several issued and pending patents.

GET IN TOUCH

REQUEST FURTHER INFORMATION. REQUEST A QUOTE.
ASK FOR AN ON-SITE DEMO.

 

Thank you so much for the Email!

Your message has already arrived! We’ll contact you shortly.

Good day.

 

PulmoTrace ApS
Skovvænget 2
DK-5620 Glamsbjerg
Denmark
Tel. +45 65 95 91 00
Fax +45 65 95 78 00

PulmoTrace, Inc.
7 Piedmont Center, Suite # 300
3525 Piedmont Road
Atlanta, GA 30305, USA
Cell +1 404 769 0588
Fax +1 404 671 9422

info@pulmotrace.com